Alexion NMO 307 Study
study and protocol number
Alexion NMO 307
ALXN1210-NMO-307
STUDY DETAILS
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)